Sign in or create an account to add this stock to your watchlist.
About Scpharmaceuticals (NASDAQ:SCPH)
scPharmaceuticals Inc., a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting. Its product pipeline also includes scFurosemide, a loop diuretic for the management of edema in patients with decompensated heart failure; scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company was founded in 2013 and is headquartered in Burlington, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:SCPH
CUSIPN/A
Phone617-517-0730
Debt
Debt-to-Equity Ratio0.10
Current Ratio19.23
Quick Ratio19.23
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$5.28 per share
Price / Book2.65
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees29
Outstanding Shares18,540,000
Scpharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions
What is Scpharmaceuticals' stock symbol?
Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."
How were Scpharmaceuticals' earnings last quarter?
Scpharmaceuticals Inc (NASDAQ:SCPH) released its quarterly earnings results on Monday, May, 7th. The company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.51) by $0.04. View Scpharmaceuticals' Earnings History.
What price target have analysts set for SCPH?
3 equities research analysts have issued 1-year target prices for Scpharmaceuticals' stock. Their predictions range from $20.00 to $26.00. On average, they anticipate Scpharmaceuticals' share price to reach $23.3333 in the next twelve months. View Analyst Ratings for Scpharmaceuticals.
Are investors shorting Scpharmaceuticals?
Scpharmaceuticals saw a increase in short interest in April. As of April 30th, there was short interest totalling 736,373 shares, an increase of 32.5% from the April 13th total of 555,763 shares. Based on an average daily trading volume, of 86,257 shares, the days-to-cover ratio is presently 8.5 days. Approximately 8.3% of the company's stock are short sold.
Who are some of Scpharmaceuticals' key competitors?
Some companies that are related to Scpharmaceuticals include TG Therapeutics (TGTX), Athenex (ATNX), CytomX Therapeutics (CTMX), Lexicon Pharmaceuticals (LXRX), Esperion Therapeutics (ESPR), Eagle Pharmaceuticals (EGRX), Flexion Therapeutics (FLXN), MacroGenics (MGNX), Omeros (OMER), Endocyte (ECYT), OptiNose (OPTN), Vanda Pharmaceuticals (VNDA), Amarin (AMRN), Assembly Biosciences (ASMB) and NuCana (NCNA).
Who are Scpharmaceuticals' key executives?
Scpharmaceuticals' management team includes the folowing people:
- Mr. John H. Tucker, Pres, CEO & Director (Age 55)
- Dr. Troy A. Ignelzi, Chief Financial Officer (Age 50)
- Mr. Abraham Ceesay, Chief Operating Officer (Age 40)
- Dr. Klaus R. Veitinger M.D., Director (Age 56)
- Dr. Pieter Muntendam M.D., Consultant (Age 60)
When did Scpharmaceuticals IPO?
(SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.
When did Scpharmaceuticals' lock-up period expire?
Scpharmaceuticals' lock-up period expired on Wednesday, May 16th. Scpharmaceuticals had issued 6,400,000 shares in its IPO on November 17th. The total size of the offering was $89,600,000 based on an initial share price of $14.00. Since the end of Scpharmaceuticals' lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company have been lifted.
Has Scpharmaceuticals been receiving favorable news coverage?
News articles about SCPH stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Scpharmaceuticals earned a coverage optimism score of 0.07 on Accern's scale. They also gave news headlines about the company an impact score of 47.24 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
Who are Scpharmaceuticals' major shareholders?
Scpharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.56%), DAFNA Capital Management LLC (0.30%), Northern Trust Corp (0.26%), Citigroup Inc. (0.21%), Schwab Charles Investment Management Inc. (0.07%) and California State Teachers Retirement System (0.06%). View Institutional Ownership Trends for Scpharmaceuticals.
Which institutional investors are selling Scpharmaceuticals stock?
Which institutional investors are buying Scpharmaceuticals stock?
SCPH stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Northern Trust Corp, Citigroup Inc., Schwab Charles Investment Management Inc. and California State Teachers Retirement System. View Insider Buying and Selling for Scpharmaceuticals.
How do I buy shares of Scpharmaceuticals?
Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Scpharmaceuticals' stock price today?
One share of SCPH stock can currently be purchased for approximately $13.98.
How big of a company is Scpharmaceuticals?
Scpharmaceuticals has a market capitalization of $259.22 million. The company earns $-23,810,000.00 in net income (profit) each year or ($8.04) on an earnings per share basis. Scpharmaceuticals employs 29 workers across the globe.
How can I contact Scpharmaceuticals?
Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]
MarketBeat Community Rating for Scpharmaceuticals (SCPH)
MarketBeat's community ratings are surveys of what our community members think about Scpharmaceuticals and other stocks. Vote "Outperform" if you believe SCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Scpharmaceuticals (NASDAQ:SCPH) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
3 Wall Street analysts have issued ratings and price targets for Scpharmaceuticals in the last 12 months. Their average twelve-month price target is $23.3333, suggesting that the stock has a possible upside of 66.91%. The high price target for SCPH is $26.00 and the low price target for SCPH is $20.00. There are currently 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | N/A |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | N/A |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $23.3333 | $23.3333 | $22.3333 | N/A |
| Price Target Upside: | 66.91% upside | 75.04% upside | 49.69% upside | N/A |
Scpharmaceuticals (NASDAQ:SCPH) Consensus Price Target History
Scpharmaceuticals (NASDAQ:SCPH) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Scpharmaceuticals (NASDAQ:SCPH) Earnings History and Estimates Chart
Scpharmaceuticals (NASDAQ:SCPH) Earnings Estimates
2018 EPS Consensus Estimate: ($3.23)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2018 | 2 | ($0.52) | ($0.50) | ($0.51) |
| Q2 2018 | 2 | ($0.66) | ($0.60) | ($0.63) |
| Q3 2018 | 2 | ($1.39) | ($0.79) | ($1.09) |
| Q4 2018 | 2 | ($1.05) | ($0.94) | ($1.00) |
Scpharmaceuticals (NASDAQ SCPH) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 5/7/2018 | Q1 2018 | ($0.51) | ($0.47) | | | View | N/A |  |
| 3/20/2018 | Q4 2017 | ($0.5270) | ($0.80) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Scpharmaceuticals (NASDAQ:SCPH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Scpharmaceuticals (NASDAQ SCPH) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 44.86%
Scpharmaceuticals (NASDAQ SCPH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/21/2017 | 5Am Partners Iv, Llc | Major Shareholder | Buy | 654,762 | $14.00 | $9,166,668.00 | | |
(Data available from 1/1/2013 forward)
Scpharmaceuticals (NASDAQ SCPH) News Headlines
| Source: |
|
Scpharmaceuticals (NASDAQ:SCPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Scpharmaceuticals (NASDAQ:SCPH) Income Statement, Balance Sheet and Cash Flow Statement
Scpharmaceuticals (NASDAQ SCPH) Stock Chart for Sunday, May, 27, 2018
Loading chart…
